These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22748259)

  • 21. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
    Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
    [No Abstract]   [Full Text] [Related]  

  • 22. Extensive tumoral melanosis associated with ipilimumab-treated melanoma.
    Staser K; Chen D; Solus J; Rosman IS; Schaffer A; Cornelius L; Linette GP; Fields RC
    Br J Dermatol; 2016 Aug; 175(2):391-3. PubMed ID: 26877232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ipilimumab in a patient with known Crohn's disease: to give or not to give?
    Gielisse EA; de Boer NK
    J Crohns Colitis; 2014 Dec; 8(12):1742. PubMed ID: 25154682
    [No Abstract]   [Full Text] [Related]  

  • 24. Long-lasting responses under treatment with ipilimumab: an argument against maintenance therapy?
    Dick J; Enk A; Hassel JC
    Dermatology; 2015; 230(1):8-10. PubMed ID: 25531526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ipilimumab induces simultaneous regression of melanocytic naevi and melanoma metastases.
    Libon F; Arrese JE; Rorive A; Nikkels AF
    Clin Exp Dermatol; 2013 Apr; 38(3):276-9. PubMed ID: 23020081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Ipilimumab treatment of metastatic melanoma].
    Ghasemi H; Schmidt H; Stolle LB
    Ugeskr Laeger; 2015 Jan; 177(2A):108-9. PubMed ID: 25612993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
    Di Giacomo AM; Ascierto PA; Pilla L; Santinami M; Ferrucci PF; Giannarelli D; Marasco A; Rivoltini L; Simeone E; Nicoletti SV; Fonsatti E; Annesi D; Queirolo P; Testori A; Ridolfi R; Parmiani G; Maio M
    Lancet Oncol; 2012 Sep; 13(9):879-86. PubMed ID: 22894884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ipilimumab with fotemustine in metastatic melanoma.
    Garbe C
    Lancet Oncol; 2012 Sep; 13(9):851-2. PubMed ID: 22894885
    [No Abstract]   [Full Text] [Related]  

  • 29. Gauging the Long-Term Benefits of Ipilimumab in Melanoma.
    Ribas A; Flaherty KT
    J Clin Oncol; 2015 Jun; 33(17):1865-6. PubMed ID: 25667273
    [No Abstract]   [Full Text] [Related]  

  • 30. Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.
    Ascierto PA
    Tumori; 2013; 99(6):302e-5e. PubMed ID: 24503809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The ipilimumab lesson in melanoma: achieving long-term survival.
    Delyon J; Maio M; Lebbé C
    Semin Oncol; 2015 Jun; 42(3):387-401. PubMed ID: 25965357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The place of PD-1 inhibitors in melanoma management.
    Bowyer S; Lorigan P
    Lancet Oncol; 2015 Aug; 16(8):873-4. PubMed ID: 26115798
    [No Abstract]   [Full Text] [Related]  

  • 33. Ipilimumab in melanoma.
    Specenier P
    Expert Rev Anticancer Ther; 2012 Dec; 12(12):1511-21. PubMed ID: 23181437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New targeted therapies in melanoma.
    Kudchadkar RR; Gonzalez R; Lewis K
    Cancer Control; 2013 Oct; 20(4):282-8. PubMed ID: 24077404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
    Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
    N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab.
    Frenard C; Peuvrel L; Jean MS; Brocard A; Knol AC; Nguyen JM; Khammari A; Quereux G; Dreno B
    J Neurooncol; 2016 Jan; 126(2):355-60. PubMed ID: 26511495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subclinical aortitis after starting nivolumab in a patient with metastatic melanoma. A case of drug-associated aortitis?
    Loricera J; Hernández JL; García-Castaño A; Martínez-Rodríguez I; González-Gay MÁ; Blanco R
    Clin Exp Rheumatol; 2018; 36 Suppl 111(2):171. PubMed ID: 29799390
    [No Abstract]   [Full Text] [Related]  

  • 39. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma.
    Zaragoza J; Caille A; Beneton N; Bens G; Christiann F; Maillard H; Machet L
    Br J Dermatol; 2016 Jan; 174(1):146-51. PubMed ID: 26343230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
    Piérard-Franchimont C; Piérard GE
    Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.